Company will decrease ongoing operating expenses, including an expected substantial reduction in organizational size, and plans to provide a further update in June DUBLIN, May 23, 2025--(BUSINESS ...

– EU approval based on NEURO-TTRansform Phase 3 results showing WAINZUA demonstrated consistent and sustained benefit improving neuropathy impairment and quality of life versus placebo ...